Bristol Myers licenses immunotherapy from Dragonfly

By The Science Advisory Board staff writers

August 10, 2020 -- Bristol Myers Squibb has paid $12 million to Dragonfly Therapeutics to license a fourth immunotherapy drug candidate from Dragonfly's TrinKet portfolio.

The deal will allow Dragonfly to further develop new natural killer cell-based treatment options for patients with cancer, autoimmune disease, and neurological conditions, it said. This is the fourth licensing agreement between the two firms since 2017.


Copyright © 2020 scienceboard.net
 


Email Address:

First Name:

Last Name:

Learn about ScienceBoard

Get the latest life sciences research and industry news, delivered straight to your inbox, for free.

Why subscribe?

ScienceBoard is uniquely focused on the business of research, addressing the biggest problems that the biomedical industry face. You’ll get breaking news, events coverage, and deep dives into the science that drives innovation, delivered to your inbox daily.

I have read and agree to the privacy policy and terms of service and wish to opt-in for ScienceBoard.net.